Key Developments: Astex Pharmaceuticals Inc (ASTX.OQ)
5.54USD
4:00pm EDT
$0.31 (+5.93%)
$5.23
$5.35
$5.59
$5.28
273,853
394,279
$6.94
$2.15
Latest Key Developments (Source: Significant Developments)
Astex Pharmaceuticals Inc Raises FY 2013 Revenue Guidance; Lowers FY 2013 Net Income Guidance
Astex Pharmaceuticals Inc announced that for fiscal 2013, revised from $55 million to $63 million, net loss has been reduced from the previous guidance of $30 million to a revised $25 million. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $59 million and net income of $(25) million for fiscal 2013. Full Article
Astex Pharmaceuticals Inc Reaffirms FY 2013 Guidance
Astex Pharmaceuticals Inc announced that guidance for fiscal 2013 remains unchanged and continues to expects total revenues of $55 million, net loss of $30 million and net loss per average share outstanding of $(0.32). According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $51 million, net income of $(67.19) million and EPS of $(0.63) for fiscal 2013. Full Article
Astex Pharmaceuticals Inc Issues FY 2013 Revenue Guidance Below Analysts' Estimates; Issues FY 2013 Earnings Guidance Above Analysts' Estimates
Astex Pharmaceuticals Inc announced that for fiscal 2013, it expects total revenues of $55 million, net loss of $30 million and net loss per average share outstanding of $(0.32). According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $67 million, net income of $(40) million and EPS of $(0.20) for fiscal 2013. Full Article
Astex Pharmaceuticals Inc Issues FY 2013 Net Income Guidance-Conference Call
Astex Pharmaceuticals Inc announced that for fiscal 2013, it expects a net loss of approximately $22 million. Full Article
Astex Pharmaceuticals, Inc. Raises FY 2012 Net Income Guidance
Astex Pharmaceuticals, Inc. revised fiscal 2012 financial guidance from a forecasted net loss of $15 million to a net loss of $5 million with the potential to be operationally cash flow positive. According to I/B/E/S Estimates, analysts were expecting the Company to report net income of $(5) million for fiscal 2012. Full Article
Astex Pharmaceuticals, Inc. Announces Initiation Of Phase II Expansion Of SGI-110 Clinical Trial In MDS And AML Patients
Astex Pharmaceuticals, Inc. announced that it has initiated the Phase II dose expansion segment of the clinical trial of SGI-110, a hypomethylating agent, in patients with intermediate-2 or high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Treatment-naive MDS and elderly AML (≥65 years) will be enrolled in the dose expansion. Enrollment in the Phase II segment is currently open, and the first patient has been dosed. The Phase II segment includes expansion of the number of patients to approximately 90 patients treated on the five day subcutaneous dosing schedule to better evaluate both efficacy and safety in MDS and AML patients. Interim Phase I clinical data from subcutaneous SGI-110 was previously reported at the American Association for Cancer Research (AACR) 2012 Annual Meeting in Chicago, IL. The data showed that SGI-110 has a clear pharmacokinetic differentiation from Dacogen (decitabine) for Injection given as an IV infusion. The drug achieved excellent hypomethylation, and clinical responses in heavily pre-treated AML patients were observed. Solid tumor Phase II trials of SGI-110 are expected to begin before the end of 2012. Full Article
Astex Pharmaceuticals, Inc. Reaffirms FY 2012 Net Loss Guidance
Astex Pharmaceuticals, Inc. announced that it is forecasting a net loss in the range from $13 million to $15 million for fiscal 2012. Full Article
Astex Pharmaceuticals, Inc. Announces Subcutaneous SGI-110 Interim Phase 1/2 MDS and AML Data Presentation At AACR
Astex Pharmaceuticals, Inc. announced that interim Phase 1/2 clinical data from subcutaneous SGI-110, a novel hypomethylating agent, demonstrated differentiated PK profile, good tolerability, and preliminary promising complete responses in heavily pretreated acute myelogenous leukemia (AML) patients enrolled in the Phase 1 segment of the trial. The data was presented at an oral session at the American Association for Cancer Research (AACR) 2012 Annual Meeting in Chicago, IL and was featured in a joint AACR-Stand Up To Cancer (SU2C) media forum. SU2C has provided funding for the Epigenetics Dream Team that is collaborating on the scientific evaluation of SGI-110. The randomized Phase 1/2 first-in-human dose escalation study enrolled 66 patients with previously treated intermediate or high-risk myelodysplastic syndromes (MDS) or AML as of March 28, 2012. Of seven evaluable refractory AML patients who had adequate hypomethylation with no prior resistance to hypomethylating agents (HMAs), two showed complete response, and one showed partial response. Additionally, the pharmacokinetic (PK) data suggests delivery of decitabine by SGI-110 achieves high decitabine exposure and longer half life than decitabine intravenous (IV) infusion. The pharmacodynamic (PD) data shows potent dose-dependent hypomethylation induction in the daily regimen. Full Article
Astex Pharmaceuticals, Inc. Issues FY 2012 Net Loss Guidance -Conference Call
Astex Pharmaceuticals, Inc. announced that it is forecasting a net loss in the range from $13 million to $15 million for fiscal 2012. Full Article
Astex Pharmaceuticals, Inc. Announces Early Transfer Of Epigenetics Project To GlaxoSmithKline
Astex Pharmaceuticals, Inc. announced the multi-year collaboration to discover cancer therapeutics based on epigenetic targets entered into by SuperGen, Inc. and GlaxoSmithKline (GSK) in November 2009 is terminating and existing research work and assets generated under the CLIMB epigenetic collaboration will be transferred to GSK. Astex will have no further obligation to conduct additional research work on the program. This decision follows on from the review and rationalization of Astex’s internal pipeline and drug discovery programs as part of the recent merger of Astex Therapeutics Limited and SuperGen, Inc. to form Astex Pharmaceuticals, Inc., and discussions with GSK. As a result of the transfer, Astex will continue to be eligible to receive milestones and royalties under an asset transfer agreement. A separate Research and Development Collaboration and License Agreement which includes a multi-target drug discovery collaboration, entered into by Astex’s UK subsidiary, Astex Therapeutics Limited and GSK in November 2009 will continue as previously announced. Full Article
BRIEF-Astex Pharmaceuticals shares up 1 pct after the bell following results
NEW YORK, April 29 - Astex Pharmaceuticals Inc : * Shares were up 1 percent after the bell following the release of its results.

Earnings vs.
Estimates